# US 2012/0252882 A1 · Cardiac-specific nucleic acid regulatory elements and methods and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252882 A1
- Document ID: US20120252882A1
- Status: Published application
- Kind: A1
- Application number: 13/504,614
- Filed: 2010-10-29
- Published: 2012-10-04
- Earliest claimed: 2009-10-29
- Assignees: Vib Vzw; Life Sciences Research Partners VZW; Universiteit Gent
- Inventors: Lay Khim Chuah; Thierry Vandendriessche; Pieter De Bleser
- Web page: https://patentgrep.com/patent/US20120252882A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 14/4716: {Muscle proteins, e.g. myosin, actin}
- C07K 14/805: Haemoglobins; Myoglobins
- C12N 15/85: for animal cells
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2799/025: where the vector is derived from a parvovirus
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/15: chimeric enhancer/promoter combination
- C12N 2830/30: being an enhancer not forming part of the promoter region
- C12N 2830/42: being an intron or intervening sequence for splicing and/or stability of RNA
- C12N 2830/85: mammalian
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to nucleic acid regulatory elements that are able to enhance cardiac-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy.

## Claims

### Claim 1

A nucleic acid regulatory element of 600 nucleotides or less for enhancing cardiac-specific gene expression, said nucleic acid regulatory element comprising a molecule selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, a molecule having 95% sequence identity to any of these molecules, and a functional fragment of any thereof.

### Claim 2 (depends on 1)

The nucleic acid regulatory element according to claim 1, comprising SEQ ID NO: 1, a sequence having 95% identity thereto, or a functional fragment thereof.

### Claim 3

A nucleic acid regulatory element of 600 nucleotides or less hybridizing under stringent conditions to a nucleic acid regulatory element of 600 nucleotides or less comprising a molecule selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, a molecule having 95% sequence identity to any of these molecules, and a functional fragment of any thereof or to its complement.

### Claim 4 (depends on 1)

The nucleic acid regulatory element of claim 1, which is 250 nucleotides or less.

### Claim 5 (depends on 1)

A nucleic acid expression cassette comprising the nucleic acid regulatory element of claim 1, operably linked to a promoter and a transgene.

### Claim 6 (depends on 1, 5)

The nucleic acid expression cassette according to claim 5, comprising two or more nucleic acid regulatory of claim 1.

### Claim 7 (depends on 6)

The nucleic acid expression cassette according to claim 6, wherein the two or more regulatory elements are identical.

### Claim 8 (depends on 5)

The nucleic acid expression cassette of claim 5, wherein the promoter is a cardiac-specific promoter.

### Claim 9 (depends on 8)

The nucleic acid expression cassette according to claim 8, wherein the promoter is from the myosin heavy chain gene.

### Claim 10 (depends on 5)

The nucleic acid expression cassette of claim 5, additionally comprising a 13-globin intron.

### Claim 11 (depends on 5)

The nucleic acid expression cassette of claim 5, wherein the transgene encodes a therapeutic protein.

### Claim 12 (depends on 1)

A vector comprising the regulatory element of claim 1.

### Claim 13 (depends on 5)

A vector comprising:
a nucleic acid regulatory element of 600 nucleotides or less comprising a molecule selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, a molecule having 95% sequence identity to any of these molecules, and a functional fragment of any thereof, and
the nucleic acid expression cassette of claim 5.

### Claim 14 (depends on 12)

The vector according to claim 12, which is a viral vector.

### Claim 15 (depends on 14)

The vector according to claim 14, which is an AAV9 vector or an AAV2/9 vector.

### Claim 16

(canceled)

### Claim 17 (depends on 5)

A method for expressing a protein in heart cells, the method comprising:
introducing in heart cells the nucleic acid expression cassette of claim 5; and
expressing the transgene protein product thereof in the heart cells.

### Claim 18 (depends on 11)

A method of gene therapy for a subject in need thereof, the method comprising:
introducing in the heart of the subject a nucleic acid expression cassette according to claim 11; and
expressing a therapeutic amount of the therapeutic protein in the liver heart.

### Claim 19 (depends on 9)

The nucleic acid expression cassette of claim 9, wherein the promoter is from the myosin heavy chain alpha (αMHC) gene.

### Claim 20 (depends on 11)

The nucleic acid expression cassette of claim 11, wherein the therapeutic protein is selected from the group consisting of an angiogenic factor, VEGF, PlGF, an ATPase, SERCA2a, an ion channel, a cytokine, and a growth factor.

### Claim 21 (depends on 3)

A vector comprising the nucleic acid regulatory element of claim 3.

### Claim 22 (depends on 14)

The vector of claim 14, wherein the vector is a lentiviral or an AAV vector.
